Targeting memory Th2 cells for the treatment of allergic asthma

https://doi.org/10.1016/j.pharmthera.2005.06.006Get rights and content

Abstract

Th2 memory cells play an important role in the pathogenesis of allergic asthma. Evidence from patients and experimental models indicates that memory Th2 cells reside in the lungs during disease remission and, upon allergen exposure, become activated effectors involved in disease exacerbation. The inhibition of memory Th2 cells or their effector functions in allergic asthma influence disease progression, suggesting their importance as therapeutic targets. They are allergen specific and can potentially be suppressed or eliminated using this specificity. They have distinct activation, differentiation, cell surface phenotype, migration capacity, and effector functions that can be targeted singularly or in combination. Furthermore, memory Th2 cells residing in the lungs can be treated locally. Capitalizing on these unique attributes is important for drug development for allergic asthma. The aim of this review is to present an overview of therapeutic strategies targeting Th2 memory cells in allergic asthma, emphasizing Th2 generation, differentiation, activation, migration, effector function, and survival.

Introduction

Allergic asthma is a chronic inflammatory disease of the conducting airways caused by an immune response directed against allergens. The syndrome affects both children and adults, resulting in loss of work and school days. It is responsible for numerous hospital visits, is a burden on the health system, and has important social and economic ramifications. Growing concern over the increase in incidence and prevalence in the last decades, in addition to increased morbidity and mortality associated with asthma, has intensified attempts to find new drug targets. Remarkably, the rise in incidence and prevalence of asthma in industrialized countries has not been adequately explained, and equally inexplicable is evidence showing that this trend is stabilizing (Lawson & Senthilselvan, 2005). Nevertheless, allergic asthma is a chronic, progressive illness, which is not influenced by diminished incidence rates. Moreover, certain patients are resistant to currently available drugs. The need for new and improved therapies is vital.

The best method of primary prevention for allergic disease is allergen avoidance. Environmental allergens, however, are impossible to elude; thus, the struggle to find improved treatments and cures persists. One strategy to cure disease is to prevent allergen sensitization, which currently is impossible because of our inability to determine susceptibility to allergic disease (atopy). Another approach is to suppress or eliminate memory CD4+ T helper (Th) 2 lymphocytes that mediate the allergic response and perpetuate allergic asthma. Th2 memory cells provide a valuable therapeutic focus in allergic asthma because of their specificity, which permits the treatment of disease without causing generalized immunosuppression.

Therapeutic strategies may be aimed at the prevention of disease or toward the inhibition of established disease. At present, it is difficult to construct novel treatments to inhibit disease initiation since the development of atopy cannot be predicted. New discoveries of genes associated with asthma, such as I-TIM1 (McIntire et al., 2004), arginase (Zimmermann et al., 2003), human thymic stromal lymphopoietin (TSLP; Soumelis et al., 2002), amongst other susceptibility genes (Hakonarson et al., 2002, Hytonen et al., 2004, Jinnai et al., 2004, Nicolae et al., 2005, Noguchi et al., 2005), however, may make it possible to establish reliable biomarkers that precede the manifestations of allergic disease. Thus, therapeutic strategies inhibiting the initial generation of memory Th2 cells must also be considered. Suppressing or eliminating Th2 cells will be most likely to ameliorate disease when the specific targeting of the approach is directed against the allergen receptor, Th2 cell, or memory Th cell. The latter 2 approaches tend to be broader and less specific than when the precise allergen is known and targeted. Inhibiting Th2 cells using non-allergen-specific methods is beneficial because the major role for Th2 immunity is in parasite defense, the loss of which is likely inconsequential in industrialized countries with few pathogenic parasites. However, inhibition of memory Th cells would cause immunosuppression, unless it was specific for memory Th2 cells. An additional consequence of Th2 suppression is a potential alteration of the balance between Th1 and Th2 immunity, leading to increased Th1 cells and autoimmunity.

Section snippets

Allergic immunity

Allergens are defined as substances that induce allergy. Common inhaled allergens are proteins derived, for example, from tree, grass and weed pollens, dust mites, molds, and animals such as dogs and cats. Ingested allergens are proteins found, for example, in seafood, peanuts, milk, and eggs. Exposure to allergens in susceptible individuals leads initially to allergen sensitization and the generation of CD4+ Th2 cells. Subsequent allergen encounters activate previously sensitized Th2 cells

Th2 cell generation

Why generate a Th2 immune response to allergens? In any battle, the main objective is to provide a first-rate defense while limiting collateral damage. Unfortunately, in the battle against pathogens, the immune system occasionally is either unable to adequately defend itself or causes unintentional harm by responding inappropriately. The immune system has evolved a defense mechanism for protecting against pathogens, which includes a strategy to avoid responding against innocuous, nonpathogenic

Immunological memory

Immunological memory is an important protective mechanism that enables host organisms to respond more rapidly and vigorously to pathogens that have been previously encountered. It is the reason why repeated infection with the same pathogen may not cause recurrent illness; it is also the basis of vaccine development. Immunological memory for bacterial and viral infections may be life saving, but, when directed against allergens, may cause morbidity and mortality. Memory immune responses are long

Targeting memory Th2 cells

The following sections will focus on the current paradigm of Th2 cell generation, activation, effector functions, and maintenance of immunological memory depicted in Fig. 2 and how it is possible to interfere with them to treat allergic asthma. It will begin with the initial encounter with allergen through to the processes that perpetuate Th2 cells and disease. The first step is allergen capture by APC and its subsequent handling and presentation, which converts a naive Th cell into an

Summary

Clinical studies and animal models have further elucidated a central role for Th2 memory cells in allergic asthma. The identification of functional pathways and genes associated with allergic asthma has had tremendous impact on the understanding of disease pathogenesis and drug discovery. The result has been specific strategies that exploit the unique properties of Th2 cells without concomitantly producing harmful immune responses or broad immunosuppression. A list of the most promising target

Acknowledgments

I would like to thank Drs. B. Mittleman, A. Baumgarten, P. Stuetz, and O. Hoffmann for their critical reading of the manuscript, discussions, and support.

References (431)

  • G.W. Canonica et al.

    Noninjection routes for immunotherapy

    J Allergy Clin Immunol

    (2003)
  • G.W. Canonica et al.

    Sublingual and oral immunotherapy

    Immunol Allergy Clin North Am

    (2004)
  • G. Caramori et al.

    Pharmacology of airway inflammation in asthma and COPD

    Pulm Pharmacol Ther

    (2003)
  • M.R. Chandok et al.

    Signaling control of memory T cell generation and function

    Semin Immunol

    (2004)
  • C.J. Corrigan et al.

    T cells and eosinophils in the pathogenesis of asthma

    Immunol Today

    (1992)
  • S. da Rocha Dias et al.

    CTLA-4 blockade of antigen-induced cell death

    Blood

    (2001)
  • V. Del Pozo et al.

    Inhibition of chronic airway inflammation and remodeling by galectin-3 gene therapy in a murine model of chronic asthma

    J Allergy Clin Immunol

    (2005)
  • C. Duez et al.

    Fas deficiency delays the resolution of airway hyperresponsiveness after allergen sensitization and challenge

    J Allergy Clin Immunol

    (2001)
  • J.H. Edwan et al.

    Treatment with Flt3 ligand plasmid reverses allergic airway inflammation in ovalbumin-sensitized and -challenged mice

    Int Immunopharmacol

    (2005)
  • L.C. Fiscus et al.

    l-Selectin is required for the development of airway hyperresponsiveness but not airway inflammation in a murine model of asthma

    J Allergy Clin Immunol

    (2001)
  • M.M. Fort et al.

    IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo

    Immunity

    (2001)
  • W.M. Abraham et al.

    A small-molecule, tight-binding inhibitor of the integrin alpha(4)beta(1) blocks antigen-induced airway responses and inflammation in experimental asthma in sheep

    Am J Respir Crit Care Med

    (2000)
  • M. Afkarian et al.

    T-bet is a STAT1-induced regulator of IL-12R expression in naive CD4+ T cells

    Nat Immunol

    (2002)
  • M. Ahmadzadeh et al.

    Heterogeneity of the memory CD4 T cell response: persisting effectors and resting memory T cells

    J Immunol

    (2001)
  • O. Akbari et al.

    Role of regulatory dendritic cells in allergy and asthma

    Curr Allergy Asthma Rep

    (2005)
  • O. Akbari et al.

    Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen

    Nat Immunol

    (2001)
  • C.A. Akdis et al.

    Role of interleukin 10 in specific immunotherapy

    J Clin Invest

    (1998)
  • C. Alexander et al.

    Fel d 1-derived T cell peptide therapy induces recruitment of CD4+ CD25+; CD4+ interferon-gamma+ T helper type 1 cells to sites of allergen-induced late-phase skin reactions in cat-allergic subjects

    Clin Exp Allergy

    (2005)
  • F.R. Ali et al.

    The potential of peptide immunotherapy in allergy and asthma

    Curr Allergy Asthma Rep

    (2002)
  • F.R. Ali et al.

    Late asthmatic reactions induced by inhalation of allergen-derived T cell peptides

    Am J Respir Crit Care Med

    (2004)
  • V. Angeli et al.

    Peroxisome proliferator-activated receptor gamma inhibits the migration of dendritic cells: consequences for the immune response

    J Immunol

    (2003)
  • C. Arikan et al.

    Bacillus Calmette-Guerin-induced interleukin-12 did not additionally improve clinical and immunologic parameters in asthmatic children treated with sublingual immunotherapy

    Clin Exp Allergy

    (2004)
  • M.A. Aronica et al.

    Recall helper T cell response: T helper 1 cell-resistant allergic susceptibility without biasing uncommitted CD4 T cells

    Am J Respir Crit Care Med

    (2004)
  • J.D. Ashwell et al.

    Glucocorticoids in T cell development and function

    Annu Rev Immunol

    (2000)
  • O. Avni et al.

    T(H) cell differentiation is accompanied by dynamic changes in histone acetylation of cytokine genes

    Nat Immunol

    (2002)
  • N.N. Bahceciler et al.

    Impact of sublingual immunotherapy on specific antibody levels in asthmatic children allergic to house dust mites

    Int Arch Allergy Immunol

    (2005)
  • P.E. Barbano et al.

    A coherent framework for multiresolution analysis of biological networks with “memory”: Ras pathway, cell cycle, and immune system

    Proc Natl Acad Sci U S A

    (2005)
  • P.G. Bardin et al.

    Methotrexate in asthma. A safety perspective

    Drug Safety

    (1993)
  • P.J. Barnes

    Cytokine modulators as novel therapies for asthma

    Annu Rev Pharmacol Toxicol

    (2002)
  • S. Basu et al.

    Toll-like receptors: function and roles in lung disease

    Am J Physiol Lung Cell Mol Physiol

    (2004)
  • A.M. Bentley et al.

    Prednisolone treatment in asthma. Reduction in the numbers of eosinophils, T cells, tryptase-only positive mast cells, and modulation of IL-4, IL-5, and interferon-gamma cytokine gene expression within the bronchial mucosa

    Am J Respir Crit Care Med

    (1996)
  • A.A. Berlin et al.

    Treatment of cockroach allergen asthma model with imatinib attenuates airway responses

    Am J Respir Crit Care Med

    (2005)
  • G. Bertorelli et al.

    Dendritic cell number is related to IL-4 expression in the airways of atopic asthmatic subjects

    Allergy

    (2000)
  • P.R. Bhathena et al.

    Interleukin-9 receptor expression in asthmatic airways in vivo

    Lung

    (2000)
  • N. Bilyk et al.

    Inhibition of the immunosuppressive activity of resident pulmonary alveolar macrophages by granulocyte/macrophage colony-stimulating factor

    J Exp Med

    (1993)
  • M.R. Blackburn et al.

    Adenosine mediates IL-13-induced inflammation and remodeling in the lung and interacts in an IL-13-adenosine amplification pathway

    J Clin Invest

    (2003)
  • M. Boguniewicz et al.

    Treatment of steroid-dependent asthma with recombinant interferon-gamma

    Clin Exp Allergy

    (1993)
  • L.C. Borish et al.

    Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial

    Am J Respir Crit Care Med

    (1999)
  • J. Bousquet

    Sublingual immunotherapy: from proven prevention to putative rapid relief of allergic symptoms

    Allergy

    (2005)
  • C.P. Broeren et al.

    Costimulation light: activation of CD4+ T cells with CD80 or CD86 rather than anti-CD28 leads to a Th2 cytokine profile

    J Immunol

    (2000)
  • Cited by (0)

    View full text